Core Viewpoint - The company announced the "Exploration Plan," committing to invest 2 billion yuan over the next five years to support innovative research in neurology and oncology [1] Group 1: Investment and Research Initiatives - The "Exploration Plan" will leverage the national key laboratory established by the company to foster disruptive innovations in drug development with significant clinical transformation potential [1] - The plan allows for rolling submissions throughout the year, with projects evaluated by the laboratory's principal investigators and authoritative experts in the field [1] - Funding, team support, and resources will be matched to the specific research proposals based on their value, prospects, and interim results [1] Group 2: Research Directions - The plan includes ten key research directions aimed at addressing high mortality and disability rates from strokes, discovering and validating potential targets for neurodegenerative diseases, and enhancing cancer treatment effectiveness [2] - It also focuses on the clinical application of next-generation gene editing technologies, RNA interference/mRNA technologies, and new cell therapy applications [2] - Additional areas of research include the clinical application of new delivery technologies, anti-aging mechanisms, and the use of AI technologies for target discovery and drug development efficacy and safety predictions [2]
先声药业宣布“求索计划” 未来5年投入20亿元